Epilepsy

At CIC Neurosciences, we conduct three types of studies: therapeutic studies (both industry-sponsored and academic), and pathophysiological studies aimed at unraveling the fundamental mechanisms of diseases in order to advance our understanding and improve patient care.

Industrial therapeutic studies

Academic therapeutic studies

Pathophysiological Studies

STACCATO (Epilepsy)

A multicenter, randomized, double-blind, placebo-controlled, outpatient, parallel-group study to evaluate the efficacy and safety of Staccato alprazolam in study participants aged 12 years and older with prolonged stereotyped seizures

🎯: To compare the efficacy of a single dose of alprazolam (staccato) versus placebo in rapidly stopping a seizure episode within 90 seconds of ME administration

⏳: Currently being added

XTOLE3

A randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as an adjunctive treatment for focal seizures

🎯: To evaluate the effect of XEN1101 compared with placebo on reducing the frequency of focal seizures.

⏳: Currently being added

At CIC Neurosciences, we conduct three types of studies: therapeutic studies (both industry-sponsored and academic), and pathophysiological studies aimed at unraveling the fundamental mechanisms of diseases in order to advance our understanding and improve patient care.

Industrial therapeutic studies

STACCATO (Epilepsy)

A multicenter, randomized, double-blind, placebo-controlled, outpatient, parallel-group study to evaluate the efficacy and safety of Staccato alprazolam in study participants aged 12 years and older with prolonged stereotyped seizures

🎯: To compare the efficacy of a single dose of alprazolam (staccato) versus placebo in rapidly stopping a seizure episode within 90 seconds of ME administration

⏳: Currently being added

XTOLE3

A randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as an adjunctive treatment for focal seizures

🎯: To evaluate the effect of XEN1101 compared with placebo on reducing the frequency of focal seizures.

⏳: Currently being added